Record margins meet growth reality checks and new leadership
- Gross margins hit 58 percent in the third quarter of 2026, proving the therapy's operating leverage.
- Second and third line patients now make up 50 percent of apheresis volume in the United States.
- Management warned that 2027 revenue estimates might be too high due to slower adoption in early lines.
- New clinical guidelines explicitly prefer CAR-T treatments over bispecific options at the first relapse.
- The company transitioned to a new permanent chief executive officer, Ingrid Zhang, in late 2026.
A strong drug navigating a slower rollout
Legend's bull case rests on CARVYKTI functioning as a sustainably profitable commercial juggernaut. That thesis gained ground in the third quarter of 2026 when gross margins crushed expectations by reaching 58 percent. New clinical guidelines now explicitly prefer CAR-T therapy over bispecific options at the first relapse. The in vivo pipeline also provided a major boost, with the LB2501 program showing a 100 percent complete response rate at dose level 2.
The bear case centers on slowing commercial momentum. Management recently cautioned that consensus 2027 revenue estimates sit at the high end of their scenarios. Community referral behavior is proving harder to change than expected, which is slowing early-line share growth in the United States. International launches are also facing delays.
Further pipeline and competitive questions remain. LB2501 showed an odd drop in efficacy at dose level 3, dropping to a 60 percent response rate. Meanwhile, competitor anito-cel faces a regulatory decision in late 2025, which will test Legend's hold on community hospitals.
One partner, one main product
Legend makes money mainly through its Janssen collaboration for CARVYKTI. Outside China, the companies share pre-tax profits and losses equally. In Greater China, Legend keeps or bears 70 percent of pre-tax profits or losses. Janssen books sales in most markets, while Legend records its share as collaboration revenue.
The financial profile reached a turning point in mid-2026, achieving sustained adjusted net income profitability. A major driver is the outpatient strategy, as treating patients outside the hospital drives volume and community adoption. Outpatient care now makes up roughly 60 percent of the mix.
While outpatient care initially pressured margins, the company proved it could offset those costs with manufacturing efficiencies. The result was a dramatic jump in gross margin to 58 percent in the third quarter of 2026, up from the low 50s.
CARVYKTI first, pipeline later
CARVYKTI
CARVYKTI is Legend's core approved therapy for multiple myeloma, commercialized globally with Janssen. It generated $710 million in global net trade sales in the third quarter of 2026.
CARTITUDE-5 and CARTITUDE-6
These trials push CARVYKTI into earlier myeloma treatment settings, aiming to widen the patient pool.
LB2501
An in vivo CD19/CD20 program for non-Hodgkin lymphoma. It recently showed a 100 percent complete response rate at dose level 2, though efficacy dropped at dose level 3.
LB2505
An in vivo BCMA-targeted therapy. It is entering a clinical study in China subject to the collaboration with Janssen.
LB2102
Legend licensed this DLL3-focused CAR-T program for small cell lung cancer to Novartis. Early data showed a 28.6 percent objective response rate.
Revenue is highly concentrated
The mix is based on fiscal 2025 revenue in Legend's Form 20-F. Collaboration revenue tied to CARVYKTI made up almost all sales.
What could break the thesis
Early-line adoption stalls
High impact · High oddsManagement warned that 2027 consensus estimates are likely too high due to slower early-line adoption in the United States and delayed international launches. Changing community referral behavior takes time.
Anito-cel pressures the market
Medium impact · Medium oddsArcellx and Gilead's anito-cel faces an FDA decision in late 2025. A clean approval and strong launch could challenge CARVYKTI's position in community oncology networks.
In vivo dose response issues
Medium impact · Medium oddsThe LB2501 program showed an unexpected efficacy drop at dose level 3 compared to dose level 2. This raises questions about the therapeutic window and optimal dosing.
Leadership transition
Medium impact · Medium oddsLegend recently transitioned to a new permanent CEO, Ingrid Zhang. A change in leadership during a critical commercial scaling phase always introduces execution risk.
In one breath
What is Legend Biotech best known for?
Legend is best known for CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma. It is the company's first and only approved product.
How does Legend Biotech make money?
Most revenue comes from the Janssen collaboration for CARVYKTI. The two companies share profits and losses, and Legend books its share as collaboration revenue.
Is Legend Biotech profitable?
Yes, the company achieved sustained adjusted net income profitability in mid-2026. Gross margins also improved to 58 percent in the third quarter of 2026.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Legend Biotech Corporation in Finn's Biotechnology industry ranking.

